{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:24:31Z","timestamp":1740165871201,"version":"3.37.3"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Norbuprenorphine interferences were observed in urine drug testing LC\u2013MS-MS confirmation methods used to assess patient compliance with prescribed buprenorphine for chronic pain and opioid use disorder. The interferences were observed in the norbuprenorphine MS-MS transitions, m\/z 414.4\/83.1 and 414.4\/187.2, at and near the norbuprenorphine retention time at multiple laboratories using different sample preparation procedures and chromatographic conditions. When the interferences were present, a norbuprenorphine result could not be reported. Upon investigation, the interferences were correlated with prescribed quetiapine (Seroquel, Seroquel XR), a second-generation antipsychotic medication approved for the treatment of schizophrenia, bipolar disorder and more recently as an adjunct treatment for major depressive disorder. In addition to the approved indications, quetiapine is prescribed off-label for other conditions including insomnia and anxiety disorders. Off-label prescribing has increased in recent years, thereby exacerbating this analytical issue. Here, we present the study of four quetiapine metabolites found to have significant direct or potential interferences in norbuprenorphine quantitation. The four metabolites were putatively identified as two hydroxyquetiapine acids differing in the site of hydroxylation and a quetiapine sulfoxide acid diastereomer pair. As a result of this study, interference-free norbuprenorphine MS-MS transitions, m\/z 414.4\/340.2 and 414.4\/326.1, were found that were selective for norbuprenorphine while maintaining an acceptable 10\u2009ng\/mL lower limit of quantitation.<\/jats:p>","DOI":"10.1093\/jat\/bkab113","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T11:07:10Z","timestamp":1635160030000},"page":"757-764","source":"Crossref","is-referenced-by-count":2,"title":["Norbuprenorphine Interferences in Urine Drug Testing LC\u2013MS-MS Confirmation Methods from Quetiapine Metabolites"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0743-6942","authenticated-orcid":false,"given":"Ana Celia","family":"Mu\u00f1oz-Mu\u00f1oz","sequence":"first","affiliation":[{"name":"Dominion Diagnostics , 211 Circuit Drive, North Kingstown, RI 02852, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Pekol","sequence":"additional","affiliation":[{"name":"CLS Diagnostics , 750 Union Street, Franklin, MA 02038, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Awad","sequence":"additional","affiliation":[{"name":"Dominion Diagnostics , 211 Circuit Drive, North Kingstown, RI 02852, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Hackett","sequence":"additional","affiliation":[{"name":"Dominion Diagnostics , 211 Circuit Drive, North Kingstown, RI 02852, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynnea","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Dominion Diagnostics , 211 Circuit Drive, North Kingstown, RI 02852, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Art","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Dominion Diagnostics , 211 Circuit Drive, North Kingstown, RI 02852, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Brelsford","sequence":"additional","affiliation":[{"name":"Dominion Diagnostics , 211 Circuit Drive, North Kingstown, RI 02852, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Engert","sequence":"additional","affiliation":[{"name":"CLS Diagnostics , 750 Union Street, Franklin, MA 02038, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Savery","sequence":"additional","affiliation":[{"name":"CLS Diagnostics , 750 Union Street, Franklin, MA 02038, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Andrade","sequence":"additional","affiliation":[{"name":"Dominion Diagnostics , 211 Circuit Drive, North Kingstown, RI 02852, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"2022081310470002800_R1","first-page":"859","article-title":"Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain","volume":"8","author":"Khanna","year":"2015","journal-title":"Journal of Pain Research"},{"key":"2022081310470002800_R2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40122-019-00143-6","article-title":"A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain","volume":"9","author":"Gudin","year":"2020","journal-title":"Pain and Therapy"},{"article-title":"National practice guideline for the use of medications in the treatment of addiction involving opioid use","year":"2020","author":"ASAM","key":"2022081310470002800_R3"},{"key":"2022081310470002800_R4","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/ALN.0b013e318238fea0","article-title":"Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active","volume":"115","author":"Brown","year":"2011","journal-title":"Anesthesiology"},{"key":"2022081310470002800_R5","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/pme.12740","article-title":"Interpretation of urine drug testing results in patients using transdermal buprenorphine preparations for the treatment of chronic noncancer pain","volume":"16","author":"Markman","year":"2015","journal-title":"Pain Medicine"},{"key":"2022081310470002800_R6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.drugalcdep.2017.07.040","article-title":"Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice","volume":"180","author":"Donroe","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"2022081310470002800_R7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jat\/32.7.516","article-title":"Urinary buprenorphine concentrations in patients treated with Suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay","volume":"32","author":"Hull","year":"2008","journal-title":"Journal of Analytical Toxicology"},{"year":"2016","key":"2022081310470002800_R8","article-title":"Seroquel prescribing information"},{"year":"2018","key":"2022081310470002800_R9","article-title":"Seroquel XR prescribing information"},{"key":"2022081310470002800_R10","first-page":"S749","article-title":"Off-label prescriptions of quetiapine for sleep disturbances","volume":"41","author":"Arts","year":"2017","journal-title":"European Psychiatry"},{"key":"2022081310470002800_R11","doi-asserted-by":"crossref","first-page":"E225","DOI":"10.9778\/cmajo.20140009","article-title":"Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study","volume":"2","author":"Pringsheim","year":"2014","journal-title":"CMAJ Open"},{"key":"2022081310470002800_R12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.9740\/mhc.2017.11.271","article-title":"Evaluation of buprenorphine\/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder","volume":"7","author":"Kapuganti","year":"2017","journal-title":"Mental Health Clinician"},{"key":"2022081310470002800_R13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/alcalc\/agw025","article-title":"Prescribed psychotropic medication use in patients receiving residential addiction treatment","volume":"51","author":"Foulds","year":"2016","journal-title":"Alcohol and Alcoholism"},{"key":"2022081310470002800_R14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2146\/ajhp070112","article-title":"Quetiapine: treatment for substance abuse and drug of abuse","volume":"65","author":"Hanley","year":"2008","journal-title":"American Journal of Health-System Pharmacy"},{"key":"2022081310470002800_R15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/2279-042X.200987","article-title":"Quetiapine misuse and abuse: is it an atypical paradigm of drug seeking behavior?","volume":"6","author":"Kim","year":"2017","journal-title":"Journal of Research in Pharmacy Practice"},{"key":"2022081310470002800_R16","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2014.13111526","article-title":"Potentiation of the effect of buprenorphine\/naloxone with gabapentin or quetiapine","volume":"171","author":"Reeves","year":"2014","journal-title":"American Journal of Psychiatry"},{"key":"2022081310470002800_R17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/rcm.3901","article-title":"In silico methods for predicting metabolism and mass fragmentation applied to quetiapine in liquid chromatography\/time-of-flight mass spectrometry urine drug screening","volume":"23","author":"Pelander","year":"2009","journal-title":"Rapid Communications in Mass Spectrometry"},{"key":"2022081310470002800_R18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/jat\/bkw078","article-title":"Quetiapine carboxylic acid and quetiapine sulfoxide prevalence in patient urine","volume":"40","author":"Strickland","year":"2016","journal-title":"Journal of Analytical Toxicology"},{"key":"2022081310470002800_R19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","article-title":"Clinical pharmacokinetics of quetiapine: an atypical antipsychotic","volume":"40","author":"DeVane","year":"2001","journal-title":"Clinical Pharmacokinetics"},{"key":"2022081310470002800_R20","first-page":"1","article-title":"New insights into quetiapine metabolism using molecular networking","volume":"10","author":"Le Dar\u00e9","year":"2020","journal-title":"Science Reports"},{"key":"2022081310470002800_R21","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":"N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine\u2019s antidepressant activity","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"2022081310470002800_R22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jat\/bkx065","article-title":"Identification of novel interferences using high-resolution mass spectrometry","volume":"42","author":"Mu\u00f1oz-Mu\u00f1oz","year":"2018","journal-title":"Journal of Analytical Toxicology"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkab113\/41131398\/bkab113.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/46\/7\/757\/45413916\/bkab113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/46\/7\/757\/45413916\/bkab113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T10:47:35Z","timestamp":1660387655000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/46\/7\/757\/6410638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,10,26]]},"published-print":{"date-parts":[[2022,8,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkab113","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"type":"print","value":"0146-4760"},{"type":"electronic","value":"1945-2403"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2021,10,26]]}}}